AXSM Axsome Therapeutics
- 91.935
- -1.755-1.87%
- 91.935
- 0.0000.00%
Axsome Therapeutics News
Optimistic Buy Rating for Axsome Therapeutics Driven by Auvelity's Strong Market Performance and Potential
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
TD Cowen Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Needham Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $133
Needham Reiterates Buy on Axsome Therapeutics, Maintains $133 Price Target
Axsome Therapeutics Analyst Ratings
Truist Financial Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $180
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Truist Financial Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $180
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $140
RBC Lifts Price Target on Axsome Therapeutics to $140 From $138, Keeps Outperform Rating
Needham Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $133
Axsome Therapeutics Analyst Ratings
William Blair Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
William Blair Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Axsome Therapeutics Price Target Cut to $122.00/Share From $124.00 by Mizuho
Axsome Therapeutics Is Maintained at Outperform by Mizuho
Leerink Partners Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $110
Cantor Fitzgerald Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $124
No Data